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Abstract
Mutations in mitochondrial small subunit ribosomal proteins MRPS16 or MRPS22 cause severe,
fatal respiratory chain dysfunction due to impaired translation of mitochondrial mRNAs. The loss
of either MRPS16 or MRPS22 was accompanied by the loss of most of another small subunit protein
MRPS11. However, MRPS2 was reduced only about 2-fold in patient fibroblasts. This observation
suggests that the small ribosomal subunit is only partially able to assemble in these patients. Two
large subunit ribosomal proteins, MRPL13 and MRPL15, were present in substantial amounts
suggesting that the large ribosomal subunit is still present despite a nonfunctional small subunit.
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1. Introduction
The 16.5 kb human mitochondrial genome encodes 22 tRNAs, 2 rRNAs and thirteen
polypeptides. These proteins, which are inserted into the inner membrane and assembled with
nuclearly encoded polypeptides, are essential components of the mitochondrial respiratory
chain complexes (MRC) I, III, IV and V. The synthesis of these 13 proteins requires a unique,
mitochondrial translational system including the unusual ribosomes found within this
organelle. Mammalian mitochondrial ribosomes are 55S particles and consist of a 28S small
subunit and a 39S large subunit (Pel et al., 1994). The small subunit includes a 12S rRNA and
an estimated 29 proteins while the large subunit contains a 16S rRNA and about 48 proteins
(Koc et al., 2000; Koc et al., 2001b). Approximately half of the mitochondrial ribosomal
proteins (MRPs) have homologs in bacteria while the remainder are unique to mitochondria
(Sharma et al., 2003). Some of the human MRP’s have no counterparts even in yeast and their
functions are largely unknown. A number of the MRPs that lack bacterial homologs appear to
have taken on novel roles in mammalian cells. For example, both MRPS27 and MRPS29 appear
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to have a role in apoptosis (Koc et al., 2001c; Mukamel et al., 2004) and several others have a
role in cell cycle control (Chen et al., 2007; Kim et al., 2005; Yoo et al., 2005). Both of the
ribosomal subunits are approximately 2/3 protein and 1/3 RNA, a ratio which is the opposite
to the ratio found in prokaryotic ribosomes. Of note, while rRNAs are encoded by
mitochondrial DNA, all the MRPs are nuclear encoded and imported from the cytosol requiring
coordination between mitochondrial transcription and cytosolic translation.
A number of mitochondrial diseases result from mutations leading to defective mitochondrial
protein synthesis and, hence, to respiratory chain deficiencies (Enriquez et al., 1995; King et
al., 1992). These disorders present a wide variety of clinical symptoms generally involving
tissues with high energy requirements. Defects in mitochondrial protein synthesis may arise
from mutations in either the nuclear or mitochondrial genomes. Diseases associated with
mutations in mitochondrial DNA, especially those affecting the tRNA genes and the12S rRNA
gene, have been extensively studied (Jacobs, 2003; Schon, 2000). However, much less is known
about a new expanding group of disorders encompassing nuclear mutations in the
mitochondrial translational machinery (Edvardson et al., 2007; Scheper et al., 2007).
In recent studies (Miller et al., 2004; Saada et al., 2007) mutations in the nuclear genes encoding
two mitochondrial small subunit ribosomal proteins were identified. The hallmarks that led to
their detection were severe respiratory chain dysfunction encompassing MRC complexes I,
III, IV and V, normal levels of complex II, normal mitochondrial DNA, normal mitochondrial
mRNAs and 16S rRNA and a significant decrease in the abundance of 12S rRNA. Since rRNA
is stable only when incorporated in a ribosomal structure, it was hypothesized that these defects
would lead to an unstable mitochondrial ribosomal small subunit while the large subunit was
expected to be intact.
A homozygous nonsense mutation (Arg111Stop) in the mitochondrial small subunit ribosomal
protein S16 (MRPS16) has been associated with agenesis of corpus callosum, dysmorphism
and fatal neonatal lactic acidosis (Miller et al., 2004). A second, homozygous, missense
mutation (R170H) in the gene encoding another small subunit ribosomal protein MRPS22 has
been associated with edema, fatal cardiomyopathy and tubulopathy (Saada et al., 2007). In
contrast to MRPS16 which is highly conserved and essential for the ribosomal small subunit
assembly, MRPS22 has no counterpart in bacteria or yeast and its function is obscure. The
availability of fibroblasts from these patients provided a unique tool for examining the human
mitochondrial ribosome. In the present study we have examined the impact of MRPS16 or
MRPS22 mutations on the small and large ribosomal subunits in order to expand our knowledge
of the human mitochondrial ribosomal assembly.
2. Material and Methods
2.1 Materials
Regular chemicals were purchased from Sigma-Aldrich or Fisher Scientific. ECL western
blotting analysis kits were purchased from GE Healthcare. ECL films were obtained from GE
Healthcare and Kodak. Protein free blocking solution was purchased from Pierce Technologies.
PVDF membranes were purchased from Millipore Corporation. Restriction enzymes were
purchased from New England Biolabs. Digested plasmids and PCR products were purified
using the Qiagen Gel Extraction/PCR Purification Kit. The cDNAs encoding human
mitochondrial ribosomal proteins MRPS2 (ATCC number MGC-16952), MRPS11 (ATCC
number MGC-40231), MRPL13 (ATCC number MGC-33899) and MRPL15 (ATCC
MGC-4898) were obtained from American Type Culture Collection (ATCC). Tissue culture
media were from Biological Industries (Beit Hemek Israel). “Assays-on-Demand Gene
Expression Products” were from Applied Biosystems and used with ImProm-II reverse
transcriptase (Promega).
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2.2 Cloning, expression and purification of MRPS2, MRPS11, MRPL13 and MRPL15
The cDNAs were amplified out of the stock pCMV-SPORT6 vectors using forward and reverse
primers with NdeI and XhoI restriction sites (underlined), respectively, as follows: MRPS2








The PCR products were digested with NdeI and XhoI and ligated into the pET21b(+) plasmid,
which provided a C-terminal His6-tag. The ligated plasmids were transformed into Stratagene’s
E. coli DH5α cells. Candidate plasmids were confirmed by sequencing and transformed into
E. coli BL21 (DE3) RIL cells (Stratagene) for expression (Koc et al., 2002).
The purification of the expressed proteins on Ni-NTA resins was carried out following the
QIAexpressionist denaturing protocol as described (Qiagen). Proteins were concentrated to a
final volume of approximately 200 μL by placing the samples into dialysis tubing and layering
them with solid PEG 8000.
2.3 Antibody Production against Mammalian MRPS2, MRPS11, MRPS16, MRPL13, and
MRPL15
Using the immunoadjuvant TiterMax Gold, a 250 μL emulsion was prepared for each factor
that contained 125 μL TiterMax and 125 μL of the concentrated protein (~250 μg). Each
emulsion was divided into two 100 μL fractions and injected into New Zealand White Rabbits
to produce the respective antibodies. The rabbits were injected at 0, 4 and 8 weeks and blood
was collected to test the serum at each injection time. The final bleed was performed at 16
weeks at which time the rabbits were exsanguinated. The specificity of the antibodies was
verified by Western blotting as described (Ma et al., 1996; Spencer et al., 2005). Antibodies
against MRPS16 were prepared in rabbits using the peptide
CPRDGRFVEQLGSYDPLPNSHGEKL conjugated to KHL as antigen (Sigma-Aldrich
Israel).
2.4 Tissue cultures and mitochondrial preparation
Fibroblast cultures were established from forearm biopsies (with informed consent). The cells
were gown in DMEM with 4.5 g glucose/L supplemented with 10% fetal calf serum, 50 μg/
mL uridine and 110 μg/mL pyruvate in an atmosphere of 5% CO2 at 37 °C. Prior to
mitochondrial isolation, the cells were incubated for 30 min in the presence of 100 μg/mL
chloramphenicol in the growth medium. Mitochondria were isolated from ten T75 tissue
culture flasks as follows; after two washes with phosphate buffered saline, the cells were
collected by scraping them into 10 mL of isolation buffer (320 mM sucrose, 2 mM EGTA, 0.1
mg/mL sodium heparin in 5 mM Tris-HCl, pH 7.3) and homogenized by nitrogen cavitation
at 450 psi (pressure bomb from Parr Instrument Moline IL) followed by a 10 min centrifugation
at 2,000 × g to pellet nuclei and unlysed cells.
The mitochondrial enriched fraction was obtained by centrifuging the supernatant at 16,000 ×
g for 10 min, the resulting pellet was re-suspended in isolation buffer containing 0.02%
digitonin and centrifuged for 10 min at 12,000 × g. The mitochondrial pellets were stored at
−70 °C until use.
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2.5 Determination of MRPS16 and MRPS22 mRNA levels
For the preparation of cDNA total mRNA (prepared from 2× 106 cells) was reverse transcribed
using ImProm-II reverse transcriptase as per the manufacturer’s instructions. The cDNA was
used in a PCR reaction to amplify and detect the expression of specific nucleic acid sequences
using the “Assays-on-Demand Gene Expression Products”. β-actin served as an endogenous
control and MRPS16 or MRPS22 as the target cDNAs. The human cytoplasmic large subunit
ribosomal protein (RPLP0) was added as an internal control target. The levels of all the cDNAs
were equalized and real-time PCR reactions were performed using each probe/primer set
separately. The experiment included mRNA prepared from 4 normal fibroblast controls and 2
patient fibroblast cell preparations performed in duplicate. The relative expression of the target
transcript was calculated with the comparative Ct method (Applied Biosystems User Manual).
2.6 Isolation of human mitochondrial ribosomes from mitochondria and detection of
mitochondrial ribosomal proteins using Western blotting
Partially purified mitochondrial ribosomes were prepared from control and patient
mitochondria as described (Spremulli, 2007). In brief, mitochondrial pellets (50 mg) from
control fibroblasts, the MRPS16-mutated patient fibroblasts or the MRPS22-mutated patient
fibroblasts were suspended in 500 μL of Base Buffer (20 mM HEPES-KOH, pH 7.6, 20 mM
MgCl2, 40 mM KCl, 2 mM dithiothreitol, 1.6% Triton X-100, 10% sucrose and 0.1 mM
phenylmethylsulfonyl fluoride) and centrifuged for 10 min at 13,000 rpm in an Eppendorf
Centrifuge. The supernatants were layered on a 3 mL cushion of 30% sucrose and the tube was
filled with Base Buffer. Samples were centrifuged for 18 h at 48,000 rpm in a Beckman Type
70.1 Ti rotor. Pellets containing ribosomes or partially assembled ribosomal particles were
dissolved in 25 μL 2x sodium dodecyl sulfate (SDS) gel loading dye (100 mM Tris-HCl, pH
6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol and 100 mM β-mercaptoethanol). A
portion of each sample (20 μL) was analyzed by SDS-polyacrylamide gel electrophoresis on
a 15% gel. Proteins were transferred to PVDF membranes and probed with the indicated
antibodies using the Enhanced Chemiluminescence (ECL) Western blotting method as
described (GE Healthcare, Amersham product booklet). Band intensities were analyzed using
the UNSCAN-IT software. Membrane stripping procedures were performed based on
Amersham ECL Western blotting product booklet.
In separate experiments whole mitochondrial pellets (15 mg each) were dissolved in 30 μL 2x
SDS gel loading dye for determining the total proteins in healthy and patient mitochondria. A
portion of each dissolved pellet (10 μL) was diluted to 20 μL by adding 2x SDS dye and heated
for 5 min. Additional β-mercaptoethanol (100 mM) was added before loading onto the SDS
gel. The levels of specific proteins were analyzed by ECL Western blotting.
3. Results
3.1 Levels of mRNAs in MRPS16 and MRPS22 fibroblasts
The deleterious mutation observed in the MRPS16 gene due to the nonsense mutation of the
Arg111Stop codon to a stop codon, was predicted to lead to the premature termination of the
MRPS16 protein. The presence of MRPS16 mRNA was not examined in the original studies.
We, therefore, measured the level of the MRPS16 mRNA by real-time PCR in cells from the
patient and from control fibroblasts. These studies indicated that, in the patient’s cells, the
MRPS16 mRNA was decreased to 13% of the levels found in normal fibroblasts while the
level of MRPS22 mRNA was unaffected (Table 1). The reduction in the level of the MRPS16
mRNA is presumably a result of nonsense mediated RNA decay (Khajavi et al.,2006). This
observation is somewhat surprising since the nonsense mutation is located in the third and last
exon of the MRPS16 gene. Nonsense mutations in the last exon are generally not good
substrates for nonsense- mediated decay. Hence, the reason for the decreased levels of the
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MRPS16 mRNA are not clear. The missense mutation in MRPS22 detected in the patients did
not lead to a significant decrease in the levels of either MRPS22 or MRPS16 mRNA (Table
1).
3.2 Effects of the mutation in MRPS16 on the levels of MRPS16 and of other ribosomal
proteins
The effect of the mutation in MRPS16 on the presence and stability of several other proteins
of the small subunit was examined using specific antibodies. For these experiments, the
mitochondria were extracted with Triton X-100 in order to free the ribosomes from the
membranes. These extracts were centrifuged through a sucrose cushion to pellet ribosomes
and partially assembled ribosomal particles, which were then analyzed for the presence of
ribosomal proteins using Western blotting. As indicated in Fig. 1, MRPS16 is readily detected
in ribosomal fractions from the control fibroblasts. As expected from the premature stop codon
and the mRNA quantitation, no MRPS16 was detected in the mitochondrial ribosomal fraction
from the patient carrying the mutated MRPS16. The predicted, truncated form encompassing
the N-terminus of MRPS16 was not observed on the Western blot suggesting that this fragment
was degraded.
In order to examine the assembly of the small ribosomal subunit in the mitochondria of the
MRPS16-mutated patient, Western analysis of ribosomal fractions from control and MRPS16-
mutated mitochondria were examined for the presence of two additional small subunit
ribosomal proteins (MRPS2 and MRPS11). As indicated in Fig. 1, the ribosomal fraction from
this patient still retained about 60% of the control levels of MRPS2. This observation suggests
that the stability of MRPS2 is not strongly affected by the defect in MRPS16, thus, it is likely
that MRPS2 is present in partially assembled ribosomal particles in the cells of the patient.
Due to limitations of the amount of material available from primary fibroblasts, it was not
possible to obtain an S-value for the partially assembled ribosomal particles present by
centrifuging them through a sucrose gradient. Notably, we intentionally chose to perform these
studies with primary (untransformed) fibroblasts, in order to reduce potential artifacts from
transformed cells; thus the amount of starting material was limited. Despite this limitation,
valuable information could be derived from the patient’s cells. Of note here is that MRPS2
from the patient’s cells could be sedimented through a sucrose cushion suggesting that it is
present in a reasonably large macromolecular complex.
In contrast to MRPS2, the level of MRPS11 was significantly reduced (over 80 %) in the
fibroblasts from the MRPS16-mutated patient (Fig. 1) indicating that the stable assembly of
MRPS11 into a macromolecular complex with other ribosomal components is quite dependent
on the presence of MRPS16. The reduction in the levels of MRPS11 in the ribosomal fraction
could be due to the degradation of this protein when not assembled into the ribosome.
Alternatively, MRPS11 could have remained un-assembled in the soluble fraction or in sub-
ribosomal particles that did not sediment in the sucrose cushion. To distinguish between these
possibilities, whole mitochondrial pellets from control and patient fibroblasts were directly
solubilized in SDS gel loading buffer and then subjected to Western analysis using the anti-
MRPS11 antibodies. While this protein was detected in whole mitochondria from control cells,
it was present in only in small amounts in the patient fibroblasts (data not shown). This
observation suggests that MRPS11 was not assembled into ribosomal particles in the absence
of MRPS16 and was subsequently degraded.
The fate of the large ribosomal subunit in the absence of a properly assembled small subunit
was examined by looking for the presence of two large subunit ribosomal proteins, MRPL13
and MRPL15. These proteins, homologs of the bacterial protein L13 and L15, are located on
the side and back of the large subunit respectively. As indicated in Fig. 1, both MRPL13 and
MRPL15 are present at the same levels in the control and patient fibroblasts. This observation
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is in agreement with the presence of normal levels of the 16S large subunit rRNA in the patient
mitochondria (Miller et al., 2004).
3.3 Effect of Mutation of MRPS22
MRPS22 is a protein specific to mitochondrial ribosomes that does not have a homolog in
bacterial, eukaryotic cytoplasmic or yeast mitochondrial ribosomes. Still it is an essential
component of the mammalian mitochondrial ribosome, since a missense mutation at position
170 changing a conserved Arg residue to His is lethal in humans (Saada et al., 2007). Nothing
is currently known about the location of MRPS22 in the ribosome or the role it may play in
ribosome assembly or function. However, the mutation of this protein causes a dramatic
reduction in the level of the 12S rRNA suggesting that it plays an important role in the stability
or assembly of the small subunit in human mitochondria (Saada et al., 2007). To examine the
effect of the mutation in MRPS22 on the presence of other ribosomal proteins, ribosomal
fractions prepared from control and MRPS22 cells were analyzed by Western blotting. The
presence of MRPS22 per se could not be tested due to the lack of available antibodies. However,
it was possible to examine these preparations for three small subunit ribosomal proteins.
Mitochondria of the MRPS22 patient show an 80–90% decrease in the levels of both MRPS11
and MRPS16 respectively (Fig. 2). This observation strongly suggests that MRPS22 plays an
important role in the assembly and stability of the mitochondrial ribosome. In its absence,
several ribosomal proteins cannot assemble into sub-ribosomal particles.
In contrast, significant amounts (about 60%) of MRPS2 are observed in the fibroblasts of the
MRPS22 patient. This observation is consistent with the finding obtained from the MRPS16-
mutated patient and suggests that a macromolecular complex containing MRPS2 can assemble
in the absence of normal ribosome assembly in human mitochondria.
Both large subunit ribosomal proteins tested (MRPL13 and MRPL15) are present in significant
amounts in the MRPS22-mutated patient mitochondria indicating that the large subunit is still
present in these cells as well (Fig. 2).
4. Discussion
Current knowledge on the structure and assembly of the mammalian mitochondrial ribosome
is limited; thus the study of human ribosomes defective in specific MRPs can potentially
contribute significant new information. MRPS16 is the homolog of the bacterial protein S16.
It is essential for viability in E. coli (Persson et al., 1995) and is clearly also essential in the
human mitochondrial ribosome. S16 is located on the lower bottom of the ribosome on the
solvent side of the small subunit (Fig. 3A). In the E. coli ribosome S16 primarily makes contact
with a number of helical segments of the 16S rRNA (Wimberly et al., 2000). However, over
half of these segments are missing in the mitochondrial ribosome. This region, like much of
the mitochondrial ribosome as a whole, is rich in proteins and MRPS16 may make a number
of protein:protein contacts that do not occur in the bacterial ribosome.
In the assembly of the bacterial 30S subunit, S16 does not initially interact with the naked
rRNA, but requires the prior binding of S4 and, to some extent S20, before incorporation into
the small subunit (Fig. 3B). Mammalian mitochondria do not contain proteins homologous to
either S4 or S20 and, hence, the incorporation of MRPS16 into the small subunit must be
dependent on other proteins (Koc et al., 2001a). A good candidate is the mitochondrial small
subunit specific protein MRPS22. The data presented here show clearly that MRPS16 is barely
detectable in fibroblasts of patients with defects in MRPS22.
MRPS11 and MRPS2 are the homologs of the corresponding bacterial proteins S11 and S2.
S11 is located on the platform of the small subunit (Fig. 3A) where is makes a number of
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contacts with other ribosomal proteins. S2 is found on the solvent side of the small subunit at
the contact between the head and the body. Both S11 and S2 are tertiary RNA binding proteins
that do not interact with the small subunit rRNA until a number of other proteins have
assembled on the RNA. The data presented here clearly indicates that MRPS11 does not
assemble well into ribosomal particles or sub-particles in either the MRPS16 or the MRPS22
mutated ribosomal particles. This observation is in contrast to observations made with respect
to the assembly of the bacterial ribosome. In bacteria (Fig. 3B), assembly of S11 into the small
subunit requires S15 followed by S6 and S18, which help create the platform on the small
subunit in conjunction with the 5′ domain of the bacterial ribosomal small subunit rRNA
(Culver,2003). This process does not require the presence of S16 in the body of the subunit.
The failure of MRPS11 to be stably incorporated into a ribosomal-like particle in the absence
of MRPS16 is intriguing and suggests that the proper formation of the platform of the small
subunit of the mitochondrial ribosome requires the proper assembly and organization of the
body of this particle.
In contrast to MRPS11, MRPS2 is able to assemble into a rapidly sedimenting particle to a
significant extent in the absence of either MRPS16 or MRPS22. This observation agrees with
the assembly process of the bacterial ribosome in which S2 incorporation is basically
independent of S16 (Fig. 3B). Independent assembly of MRPS2 may reflect the ability of the
head/neck of the small subunit encompassing the 3′ major domain of the rRNA to assemble
into an independent subcomplex containing a number of ribosomal proteins including S2
(Samaha et al., 1994). The formation of this complex may account for the presence of MRPS2
in the mutated cell lines.
Finally, the results presented here suggest that the large subunit can be assembled and remain
stable in the absence of a functional small subunit of the mitochondrial ribosome corroborating
the previous assumption based on the presence of the 16S rRNA. This observation suggests
that there is no regulatory cross-talk monitoring the levels of the large and small subunits in
the mitochondrion. Since the rRNAs in both subunits are co-transcribed, such a regulatory
mechanism would presumably not be necessary. Examining the ribosomes from patients with
defective MRP’s provides a unique tool to study the human mitochondrial translation system
and ribosomal assembly in particular. An expanded knowledge of this machinery may advance
research towards developing therapeutic options.
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Identification of human mitochondrial ribosomal proteins in control and MRPS16 patient cells.
(A) The levels of patient mitochondrial ribosomal proteins MRPS16, MRPS2, MRPS11,
MRPL13 and MRPL15 from healthy control and MRPS16 cells were determined by Western
blotting using antibodies against the specified protein and detected by ECL. The background
of the blots varied due the type of the film used, the exposure time and the number of times
the membrane was re-probed. In each case, control and patient mitochondria were examined
under the same conditions. The antibody used is indicated as the probe above the given lanes.
(B) Quantification of the amount of the indicated protein present in fibroblast mitochondria
from the MRPS16 patient compared to the amount present in control cells. Relative band
intensity was determined using the UNSCAN-IT software.
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Identification of human mitochondrial ribosomal proteins of control and MRPS22 patient cells.
(A) The levels of mitochondrial ribosomal proteins MRPS16, MRPS2, MRPS11, MRPL13
and MRPL15 were examined in mitochondria derived from control and MRPS22 cells using
Western blotting and the indicated antibody as a probe. The backgrounds on the blots depended
on the type of film used, and the number of times the membranes were stripped for reprobing.
(B) Quantification of the amount of the indicated protein present in fibroblast mitochondria
from the MRPS16 patient compared to the amount present in control cells. Relative band
intensities were determined using the SCAN-IT software.
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The small subunit of the bacterial ribosome and its assembly. (A) The positions of S16, S11
and S2 in the small subunit of the bacterial ribosome are indicated. The model is based on the
pdb coordinates of the 30S subunit from Thermus thermophilus (2J00) and displayed using
Pymol (DeLano, W.L. The PyMOL Molecular Graphics System (2002) on World Wide Web
http://www.pymol.org). The rRNA is shown in gold, S16 is space-filled in turquoise, S11 is
space-filled in red and S2 is in dark blue. Other ribosomal proteins are shown as ribbon
structures. (B) Modified assembly map for the 30S subunit from E. coli indicating the positions
in the assembly observed with bacterial S16, S11 and S2. This map is based on an updated
map presented in (Culver, 2003). Red circles indicate proteins that are not present in the
mammalian mitochondrial ribosome. Mammalian mitochondrial ribosomal protein MRPS22
is shown in the map but its position is clearly hypothetical. Possible connections to other
proteins are shown in dotted lines. The proteins that are primary RNA binding proteins in E.
coli are in black; secondary RNA binding proteins are in blue while tertiary RNA binding
proteins are red.
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Table 1
Quantification of MRPS16 and MRPS22 transcripts1
Fibroblasts Relative amount of mRNA present
RPLP0 MRPS 16 MRPS 22
MRPS16 patient 0.84 0.13 0.99
MRPS22 patient 0.85 0.73 0.81
Controls (n=4) 1.0 1.0 1.0
1
The levels of mRNA’s were determined by quantitative RT-PCR and quantified relative to β-actin levels in 4 normal control fibroblasts.
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